Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer

NCT01927341 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01927341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01927341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
November 19, 2013
Completion date
January 25, 2016
Enrollment
53 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer